Loading…

Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma

Introduction Hepatocellular carcinoma (HCC) is a common primary hepatic cancer. Its early diagnosis can aid in its treatment by curative means such as surgery or ablation. Advanced-stage diagnosis limits these treatment options, and such cases can be treated with transarterial chemoembolization (TAC...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-07, Vol.15 (7), p.e41701-e41701
Main Authors: Adel, Hatem, Shazlee, Muhammad K, Qamar, Saqib, Hyder, Syed Muhammad Shahnawaz, Razaque, Abdul
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c300t-2164885f2593588014d93bfe582b279b88721594770a91270d43be1b1d54a80f3
container_end_page e41701
container_issue 7
container_start_page e41701
container_title Curēus (Palo Alto, CA)
container_volume 15
creator Adel, Hatem
Shazlee, Muhammad K
Qamar, Saqib
Hyder, Syed Muhammad Shahnawaz
Razaque, Abdul
description Introduction Hepatocellular carcinoma (HCC) is a common primary hepatic cancer. Its early diagnosis can aid in its treatment by curative means such as surgery or ablation. Advanced-stage diagnosis limits these treatment options, and such cases can be treated with transarterial chemoembolization (TACE). Conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are usually used, and follow-up response is evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. This study was done to compare the treatment response of cTACE and DEB-TACE in patients with HCC. Materials and methods A retrospective review of electronic medical records of all patients diagnosed with HCC from January 2021 to August 2022 who underwent cTACE or DEB-TACE was undertaken at the Department of Interventional Radiology, Indus Hospital and Health Network. Both male and female patients aged 18 years or above with Child-Pugh class A and B were included. DEB-TACE or cTACE was performed by a fellowship-trained interventional radiologist, and the response was evaluated at six weeks follow-up using mRECIST criteria. Results A total of 129 patients were included in this study, with a mean age of 54.1 ± 10.8 years. The mean size of HCC was 3.1 ± 1.7 cm. Seventy-eight (60.5%) patients underwent cTACE, and 51 (39.5%) underwent DEB-TACE. Out of the 78 patients who underwent cTACE, complete response (CR) was found in 28 (35.9%), partial response (PR) was found in 33 (42.3%), stable disease (SD) was found in 12 (15.4%), and progressive disease (PD) was found in five (6.4%) patients. Of the 51 patients who underwent DEB-TACE, CR was found in 13 (25.5%), PR was found in 20 (39.2%), SD was found in 11 (21.6%), and PD was found in seven (13.7%) patients. Conclusion The response rate of TACE in the form of complete or partial response was higher with a lower frequency of stable or progressive disease. cTACE has a high response rate as compared to DEB-TACE.
doi_str_mv 10.7759/cureus.41701
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414135</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2850716045</sourcerecordid><originalsourceid>FETCH-LOGICAL-c300t-2164885f2593588014d93bfe582b279b88721594770a91270d43be1b1d54a80f3</originalsourceid><addsrcrecordid>eNqFkkFrFTEQx4MottTePEvAiwe3JtmkyZ5E12qFgiIVj2F2d_a9lN1kTbIF_Vx-QPP6aqleZA6ZML_5MzP8CXnK2YnWqnnVrxHXdCK5ZvwBORT81FSGG_nwXn5AjlO6YoxxpgXT7DE5qLUqofUh-dWGeYHoUvA0jDRvkV5GhDyjz_QLpiX4hLvKu7huqrNpzc5v6FuEoXDgE8SM0cFE2y3OAecuTO4nZFfkwA-0Df66KJVvQf7X4Dz9XLLCJ_rN5S09xwVy6HGa1gkibSH2zocZnpBHI0wJj2_fI_L1_dlle15dfPrwsX1zUfU1Y7kqF5DGqFGoplbGMC6Hpu5GVEZ0QjedMVpw1UitGTRcaDbIukPe8UFJMGysj8jrve6ydjMOfZkswmSX6GaIP2wAZ_-ueLe1m3BtOZNc8loVhRe3CjF8XzFlO7u0Wwg8hjVZYRTT_JTJHfr8H_QqrLHc7YZqpBJcsEK93FN9DClFHO-m4czuLGH3lrA3lij4s_sb3MF_DFD_Bn4NtvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2859452120</pqid></control><display><type>article</type><title>Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma</title><source>Publicly Available Content Database</source><source>PubMed Central(OpenAccess)</source><creator>Adel, Hatem ; Shazlee, Muhammad K ; Qamar, Saqib ; Hyder, Syed Muhammad Shahnawaz ; Razaque, Abdul</creator><creatorcontrib>Adel, Hatem ; Shazlee, Muhammad K ; Qamar, Saqib ; Hyder, Syed Muhammad Shahnawaz ; Razaque, Abdul</creatorcontrib><description>Introduction Hepatocellular carcinoma (HCC) is a common primary hepatic cancer. Its early diagnosis can aid in its treatment by curative means such as surgery or ablation. Advanced-stage diagnosis limits these treatment options, and such cases can be treated with transarterial chemoembolization (TACE). Conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are usually used, and follow-up response is evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. This study was done to compare the treatment response of cTACE and DEB-TACE in patients with HCC. Materials and methods A retrospective review of electronic medical records of all patients diagnosed with HCC from January 2021 to August 2022 who underwent cTACE or DEB-TACE was undertaken at the Department of Interventional Radiology, Indus Hospital and Health Network. Both male and female patients aged 18 years or above with Child-Pugh class A and B were included. DEB-TACE or cTACE was performed by a fellowship-trained interventional radiologist, and the response was evaluated at six weeks follow-up using mRECIST criteria. Results A total of 129 patients were included in this study, with a mean age of 54.1 ± 10.8 years. The mean size of HCC was 3.1 ± 1.7 cm. Seventy-eight (60.5%) patients underwent cTACE, and 51 (39.5%) underwent DEB-TACE. Out of the 78 patients who underwent cTACE, complete response (CR) was found in 28 (35.9%), partial response (PR) was found in 33 (42.3%), stable disease (SD) was found in 12 (15.4%), and progressive disease (PD) was found in five (6.4%) patients. Of the 51 patients who underwent DEB-TACE, CR was found in 13 (25.5%), PR was found in 20 (39.2%), SD was found in 11 (21.6%), and PD was found in seven (13.7%) patients. Conclusion The response rate of TACE in the form of complete or partial response was higher with a lower frequency of stable or progressive disease. cTACE has a high response rate as compared to DEB-TACE.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.41701</identifier><identifier>PMID: 37575777</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Age ; Chemoembolization ; Chi-square test ; Developing countries ; Embolization ; Females ; Gastroenterology ; Gender ; Ischemia ; LDCs ; Liver cancer ; Males ; Medical records ; Oncology ; Patients ; Polyvinyl alcohol ; Radiology ; Tumors ; Veins &amp; arteries</subject><ispartof>Curēus (Palo Alto, CA), 2023-07, Vol.15 (7), p.e41701-e41701</ispartof><rights>Copyright © 2023, Adel et al.</rights><rights>Copyright © 2023, Adel et al. This work is published under https://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2023, Adel et al. 2023 Adel et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c300t-2164885f2593588014d93bfe582b279b88721594770a91270d43be1b1d54a80f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2859452120/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2859452120?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37575777$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adel, Hatem</creatorcontrib><creatorcontrib>Shazlee, Muhammad K</creatorcontrib><creatorcontrib>Qamar, Saqib</creatorcontrib><creatorcontrib>Hyder, Syed Muhammad Shahnawaz</creatorcontrib><creatorcontrib>Razaque, Abdul</creatorcontrib><title>Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Introduction Hepatocellular carcinoma (HCC) is a common primary hepatic cancer. Its early diagnosis can aid in its treatment by curative means such as surgery or ablation. Advanced-stage diagnosis limits these treatment options, and such cases can be treated with transarterial chemoembolization (TACE). Conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are usually used, and follow-up response is evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. This study was done to compare the treatment response of cTACE and DEB-TACE in patients with HCC. Materials and methods A retrospective review of electronic medical records of all patients diagnosed with HCC from January 2021 to August 2022 who underwent cTACE or DEB-TACE was undertaken at the Department of Interventional Radiology, Indus Hospital and Health Network. Both male and female patients aged 18 years or above with Child-Pugh class A and B were included. DEB-TACE or cTACE was performed by a fellowship-trained interventional radiologist, and the response was evaluated at six weeks follow-up using mRECIST criteria. Results A total of 129 patients were included in this study, with a mean age of 54.1 ± 10.8 years. The mean size of HCC was 3.1 ± 1.7 cm. Seventy-eight (60.5%) patients underwent cTACE, and 51 (39.5%) underwent DEB-TACE. Out of the 78 patients who underwent cTACE, complete response (CR) was found in 28 (35.9%), partial response (PR) was found in 33 (42.3%), stable disease (SD) was found in 12 (15.4%), and progressive disease (PD) was found in five (6.4%) patients. Of the 51 patients who underwent DEB-TACE, CR was found in 13 (25.5%), PR was found in 20 (39.2%), SD was found in 11 (21.6%), and PD was found in seven (13.7%) patients. Conclusion The response rate of TACE in the form of complete or partial response was higher with a lower frequency of stable or progressive disease. cTACE has a high response rate as compared to DEB-TACE.</description><subject>Age</subject><subject>Chemoembolization</subject><subject>Chi-square test</subject><subject>Developing countries</subject><subject>Embolization</subject><subject>Females</subject><subject>Gastroenterology</subject><subject>Gender</subject><subject>Ischemia</subject><subject>LDCs</subject><subject>Liver cancer</subject><subject>Males</subject><subject>Medical records</subject><subject>Oncology</subject><subject>Patients</subject><subject>Polyvinyl alcohol</subject><subject>Radiology</subject><subject>Tumors</subject><subject>Veins &amp; arteries</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqFkkFrFTEQx4MottTePEvAiwe3JtmkyZ5E12qFgiIVj2F2d_a9lN1kTbIF_Vx-QPP6aqleZA6ZML_5MzP8CXnK2YnWqnnVrxHXdCK5ZvwBORT81FSGG_nwXn5AjlO6YoxxpgXT7DE5qLUqofUh-dWGeYHoUvA0jDRvkV5GhDyjz_QLpiX4hLvKu7huqrNpzc5v6FuEoXDgE8SM0cFE2y3OAecuTO4nZFfkwA-0Df66KJVvQf7X4Dz9XLLCJ_rN5S09xwVy6HGa1gkibSH2zocZnpBHI0wJj2_fI_L1_dlle15dfPrwsX1zUfU1Y7kqF5DGqFGoplbGMC6Hpu5GVEZ0QjedMVpw1UitGTRcaDbIukPe8UFJMGysj8jrve6ydjMOfZkswmSX6GaIP2wAZ_-ueLe1m3BtOZNc8loVhRe3CjF8XzFlO7u0Wwg8hjVZYRTT_JTJHfr8H_QqrLHc7YZqpBJcsEK93FN9DClFHO-m4czuLGH3lrA3lij4s_sb3MF_DFD_Bn4NtvQ</recordid><startdate>20230711</startdate><enddate>20230711</enddate><creator>Adel, Hatem</creator><creator>Shazlee, Muhammad K</creator><creator>Qamar, Saqib</creator><creator>Hyder, Syed Muhammad Shahnawaz</creator><creator>Razaque, Abdul</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230711</creationdate><title>Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma</title><author>Adel, Hatem ; Shazlee, Muhammad K ; Qamar, Saqib ; Hyder, Syed Muhammad Shahnawaz ; Razaque, Abdul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c300t-2164885f2593588014d93bfe582b279b88721594770a91270d43be1b1d54a80f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Chemoembolization</topic><topic>Chi-square test</topic><topic>Developing countries</topic><topic>Embolization</topic><topic>Females</topic><topic>Gastroenterology</topic><topic>Gender</topic><topic>Ischemia</topic><topic>LDCs</topic><topic>Liver cancer</topic><topic>Males</topic><topic>Medical records</topic><topic>Oncology</topic><topic>Patients</topic><topic>Polyvinyl alcohol</topic><topic>Radiology</topic><topic>Tumors</topic><topic>Veins &amp; arteries</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adel, Hatem</creatorcontrib><creatorcontrib>Shazlee, Muhammad K</creatorcontrib><creatorcontrib>Qamar, Saqib</creatorcontrib><creatorcontrib>Hyder, Syed Muhammad Shahnawaz</creatorcontrib><creatorcontrib>Razaque, Abdul</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adel, Hatem</au><au>Shazlee, Muhammad K</au><au>Qamar, Saqib</au><au>Hyder, Syed Muhammad Shahnawaz</au><au>Razaque, Abdul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2023-07-11</date><risdate>2023</risdate><volume>15</volume><issue>7</issue><spage>e41701</spage><epage>e41701</epage><pages>e41701-e41701</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Introduction Hepatocellular carcinoma (HCC) is a common primary hepatic cancer. Its early diagnosis can aid in its treatment by curative means such as surgery or ablation. Advanced-stage diagnosis limits these treatment options, and such cases can be treated with transarterial chemoembolization (TACE). Conventional transarterial chemoembolization (cTACE) and drug-eluting bead transarterial chemoembolization (DEB-TACE) are usually used, and follow-up response is evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST) criteria. This study was done to compare the treatment response of cTACE and DEB-TACE in patients with HCC. Materials and methods A retrospective review of electronic medical records of all patients diagnosed with HCC from January 2021 to August 2022 who underwent cTACE or DEB-TACE was undertaken at the Department of Interventional Radiology, Indus Hospital and Health Network. Both male and female patients aged 18 years or above with Child-Pugh class A and B were included. DEB-TACE or cTACE was performed by a fellowship-trained interventional radiologist, and the response was evaluated at six weeks follow-up using mRECIST criteria. Results A total of 129 patients were included in this study, with a mean age of 54.1 ± 10.8 years. The mean size of HCC was 3.1 ± 1.7 cm. Seventy-eight (60.5%) patients underwent cTACE, and 51 (39.5%) underwent DEB-TACE. Out of the 78 patients who underwent cTACE, complete response (CR) was found in 28 (35.9%), partial response (PR) was found in 33 (42.3%), stable disease (SD) was found in 12 (15.4%), and progressive disease (PD) was found in five (6.4%) patients. Of the 51 patients who underwent DEB-TACE, CR was found in 13 (25.5%), PR was found in 20 (39.2%), SD was found in 11 (21.6%), and PD was found in seven (13.7%) patients. Conclusion The response rate of TACE in the form of complete or partial response was higher with a lower frequency of stable or progressive disease. cTACE has a high response rate as compared to DEB-TACE.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>37575777</pmid><doi>10.7759/cureus.41701</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2023-07, Vol.15 (7), p.e41701-e41701
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10414135
source Publicly Available Content Database; PubMed Central(OpenAccess)
subjects Age
Chemoembolization
Chi-square test
Developing countries
Embolization
Females
Gastroenterology
Gender
Ischemia
LDCs
Liver cancer
Males
Medical records
Oncology
Patients
Polyvinyl alcohol
Radiology
Tumors
Veins & arteries
title Comparison of the Treatment Response of Drug-Eluting Bead Transarterial Chemoembolization and Conventional Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T20%3A56%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20Treatment%20Response%20of%20Drug-Eluting%20Bead%20Transarterial%20Chemoembolization%20and%20Conventional%20Transarterial%20Chemoembolization%20in%20Patients%20With%20Hepatocellular%20Carcinoma&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Adel,%20Hatem&rft.date=2023-07-11&rft.volume=15&rft.issue=7&rft.spage=e41701&rft.epage=e41701&rft.pages=e41701-e41701&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.41701&rft_dat=%3Cproquest_pubme%3E2850716045%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c300t-2164885f2593588014d93bfe582b279b88721594770a91270d43be1b1d54a80f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2859452120&rft_id=info:pmid/37575777&rfr_iscdi=true